Sol Gel - New Logo - light.jpg
Sol-Gel Technologies Announces Management Realignment
15 juil. 2024 07h00 HE | Sol-Gel Technologies Ltd.
Sol-Gel Technologies Announces Management Realignment
logo.png
PSYC Provides Shareholders with Key Corporate Updates and Highlights Objectives for 2023
31 janv. 2023 08h30 HE | PSYC Corporation
LAS VEGAS, NV, Jan. 31, 2023 (GLOBE NEWSWIRE) -- PSYC Corporation (OTC Pink Market: PSYC) (“PSYC”, “PSYC Corp” or the “Company”), parent company to Spotlight Media Corporation (“SMC” or the “wholly...
Logo.jpg
Bell Buckle Holdings, Inc. Updates Shareholders and Enters into Discussions with Two Operating Companies
17 févr. 2022 15h15 HE | Bell Buckle Holdings, Inc.
Naples, FL, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Bell Buckle Holdings Inc. (OTC Pink: BLLB) (“The Company”) is pleased to update shareholders on our progress in 2022 and continues to execute on our...
Logo.jpg
Bell Buckle Holdings Confirms Removal of Caveat Emptor Designation and Provides Corporate Updates
25 janv. 2022 06h00 HE | Bell Buckle Holdings, Inc.
Naples, FL, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Bell Buckle Holdings Inc. (OTC Pink: BLLB) (“The Company”) is pleased to announce that the Caveat Emptor Designation has been removed and the Company is...
logo_vemanti.jpg
Vemanti Group Announces Corporate Updates and Developments
01 juil. 2020 08h30 HE | Vemanti Group, Inc
IRVINE, Calif., July 01, 2020 (GLOBE NEWSWIRE) -- Vemanti Group, Inc. (OTC PINK:VMNT) a multi-asset technology-driven company, today provided its corporate updates and developments. The Company’s Q2...
logo.png
Corbus Pharmaceuticals Reports First Quarter Financial Results and Corporate Updates
11 mai 2020 07h05 HE | Corbus Pharmaceuticals Holdings, Inc.
Topline results for lenabasum Phase 3 RESOLVE-1 study in systemic sclerosis remain on schedule for summer of 2020, followed by Phase 2b study data in cystic fibrosis Phase 1 trial of CRB-4001 remains...
logo.png
Corbus Pharmaceuticals Reports 2019 Third Quarter Financial Results and Provides Clinical and Corporate Updates
07 nov. 2019 07h05 HE | Corbus Pharmaceuticals Holdings, Inc.
Phase 3 “RESOLVE-1” study of lenabasum for treatment of systemic sclerosis on track for topline results in summer of 2020Systemic sclerosis is a rare autoimmune disease affecting ~200,000 people in...
j552c5be060d4d1000956f900_logo.jpg
Bullfrog Gold Receives Nevada Permits and Provides Corporate and Project Updates
15 juil. 2019 06h00 HE | Bullfrog Gold Corp
GRAND JUNCTION, Colo., July 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Bullfrog Gold Corp (OTCQB: BFGC) (“BFGC” or the “Company”) is pleased to announce issuance of environmental permits and...
Vitality New.png
Vitality Biopharma Announces Corporate Updates and Completion of an SEC Examination
21 nov. 2018 07h00 HE | Vitality Biopharma, Inc
Company appoints two new directors including the Hon. Edward Feighan as new Chairman of the Board LOS ANGELES, Nov. 21, 2018 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTCQB: VBIO)...